Lamivudine treatment in patients with decompensated liver disease due to HBeAg negative chronic hepatitis B. A multicenter study.

被引：0
|
作者：
Manolakopoulos, S
Karatapanis, S
Elefsiniotis, J
Goulis, J
Mathou, N
Vlachogiannakos, J
Iliadou, E
Kougioumtzan, A
Economou, M
Tzourmakliotis, D
Avgerinos, A
机构：
[1] Polyclin Gen Hosp, Athens, Greece
[2] Gen Hosp Athens Elpis, Athens, Greece
[3] Elena Venizelou Hosp, Athens, Greece
[4] Evangelismos Gen Hosp, Athens, Greece
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1930
引用
收藏
页码：645A / 645A
页数：1
相关论文
共 50 条
  • [41] Efficacy of Lamivudine in patients with cirrhosis due to hepatitis B.
    Moskovitz, DN
    Lilly, LB
    Tomlinson, G
    Heathcote, J
    HEPATOLOGY, 2001, 34 (04) : 625A - 625A
  • [42] Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection
    Yao, FY
    Bass, NM
    JOURNAL OF HEPATOLOGY, 2000, 33 (02) : 301 - 307
  • [43] Outcome of patients with HBeAg negative hepatitis B awaiting liver transplantation (OLT) treated with lamivudine
    Andreone, P
    Biselli, M
    Munira, H
    Lok, ASF
    Romano, S
    Gramenzi, A
    Cursaro, C
    Bernardi, M
    JOURNAL OF HEPATOLOGY, 2001, 34 : 31 - 31
  • [44] Immunotherapy by concomitant hepatitis B vaccination for the chronic hepatitis B patients during lamivudine treatment: A pilot study.
    Park, J
    Yoo, BC
    Kim, JH
    Kim, HJ
    Do, JH
    Park, SM
    HEPATOLOGY, 2001, 34 (04) : 626A - 626A
  • [45] Lamivudine reduces the need for liver transplantation and improves survival in patients with severely decompensated cirrhosis due to active hepatitis B infection: A controlled study.
    Yao, FY
    Terrault, NA
    Friese, CE
    Maslow, L
    Bass, NM
    HEPATOLOGY, 2000, 32 (04) : 457A - 457A
  • [46] LONG-TERM OUTCOME OF LAMIVUDINE RESPONDER HBeAg NEGATIVE CHRONIC HEPATITIS B PATIENTS
    Ceylan, Bahadir
    Fincanci, Muzaffer
    Muderrisoglu, Cuneyt
    Soysal, Ferda
    Eren, Gulhan
    NOBEL MEDICUS, 2011, 7 (03): : 60 - 65
  • [47] Impact of IFN on progression of liver disease in hepatitis B "E" antigen (HBEAG) negative chronic hepatitis B (CHB) patients: A long term Italian multicenter AISF study
    Oliveri, F
    Puoti, M
    Santantonio, T
    Lampertico, P
    Colloredo, G
    Niro, G
    Fattovich, G
    Morisco, F
    Marrone, A
    Costa, P
    Felder, M
    Cacciatore, P
    Smedile, A
    Brunetto, MR
    HEPATOLOGY, 2005, 42 (04) : 577A - 578A
  • [48] Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B
    Arase, Yasnji
    Ikeda, Kenji
    Suzuki, Fumitaka
    Suzuki, Yoshiyuki
    Kobayashi, Masahiro
    Akuta, Norio
    Hosaka, Tetsuya
    Sezaki, Hitomi
    Yatsuji, Hiromi
    Kawamura, Yusuke
    Kobayashi, Mariko
    Kumada, Hiromitsu
    JOURNAL OF MEDICAL VIROLOGY, 2007, 79 (09) : 1286 - 1292
  • [49] HBSAG SEROCOVERSION UNDER LAMIVUDINE IN HBEAG-NEGATIVE CHRONIC HEPATITIS B
    Seven, Gulseren
    Idilman, Ramazan
    Bozkus, Yusuf
    Cinar, Kubilay
    Kabacam, Gokhan
    Yakut, Mustafa
    Bozdayi, A. Mithat
    Yurdaydin, Cihan
    HEPATOLOGY, 2010, 52 (04) : 545A - 546A
  • [50] Efficacy of long term lamivudine therapy in HBeAG negative chronic hepatitis B
    Dimou, E
    Papatheodoridis, GV
    Laras, A
    Hadziyannis, SJ
    JOURNAL OF HEPATOLOGY, 2000, 32 : 98 - 98
12345